P/E at 36.06 vs Industry's 36.96: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Slight Discount to Industry Average

The P/E ratio of Sun Pharmaceutical Industries Ltd at 36.06 is just below the sector average of 36.96, indicating that the stock is trading at a modest discount relative to its peers. This near-parity suggests that the market values the company’s earnings in line with industry expectations, neither assigning a significant premium nor discount. Given the large-cap status and a market capitalisation of ₹4,55,837.65 crores, this valuation reflects a balance between growth prospects and risk factors inherent in the Pharmaceuticals & Biotechnology sector. The question remains — previously rated Hold, what is Sun Pharma’s current rating? The four-parameter analysis factors in the valuation premium.

Performance Across Timeframes: Divergent Momentum

Examining returns over various periods reveals a complex momentum profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 19.14% gain, significantly outperforming the Sensex’s 5.36% loss. This strong annual performance is further supported by a three-month return of 6.52%, which also surpasses the Sensex’s 2.89% rise. However, the short-term trend is less encouraging: the stock has declined by 2.87% over the past week and 2.52% over the last month, both underperforming the Sensex’s respective declines of 0.74% and 2.69%. This recent weakness is compounded by a three-day consecutive fall, resulting in a cumulative loss of 1.91%. The 0.04% gain on the latest trading day was inline with the sector’s performance, but the short-term softness raises questions about near-term momentum — is this a genuine recovery or a relief rally that will fade at the 50 DMA? The 5% surge partially reverses a 6.45% monthly decline — the moving average configuration provides the clearest answer.

Moving Average Configuration: Mixed Technical Signals

The technical picture for Sun Pharmaceutical Industries Ltd is characterised by a nuanced moving average (MA) configuration. The stock currently trades above its 100-day and 200-day moving averages, signalling that the longer-term trend remains intact and supportive. However, it is trading below the 5-day, 20-day, and 50-day moving averages, indicating short-term pressure and a potential consolidation or correction phase. This configuration suggests a recent bounce within a larger uptrend, but the inability to surpass the intermediate MAs points to resistance and uncertainty in the near term. The interplay between these moving averages often acts as a barometer for trend strength and potential reversals, raising the question — is this a recovery or a dead-cat bounce?

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Out of 34 stocks that have declared results, 14 reported positive outcomes, 15 remained flat, and 5 posted negative results. This distribution indicates a sector grappling with varied operational and market challenges. Within this environment, Sun Pharmaceutical Industries Ltd’s ability to outperform the Sensex over multiple timeframes is notable, though the recent short-term softness aligns with some sector peers facing headwinds. The sector’s overall performance underscores the importance of analysing individual stock dynamics rather than relying solely on broad sector trends.

Rating Context: Previously Rated Buy, Now Reassessed

MarketsMOJO had previously assigned a Buy rating to Sun Pharmaceutical Industries Ltd, with a Mojo Score of 67.0. The rating was updated on 03 Sep 2026, reflecting a reassessment of the company’s fundamentals, valuation, and technicals. While the current rating is not disclosed, the shift from Buy to Hold status signals a more cautious stance. This change invites investors to consider the underlying data carefully — should investors in Sun Pharma hold, buy more, or reconsider? The current rating provides the answer.

Long-Term Performance: Strong Gains Over Multiple Years

Looking beyond the short and medium term, Sun Pharmaceutical Industries Ltd has delivered impressive returns over longer horizons. The three-year return stands at 67.66%, significantly outperforming the Sensex’s 15.27%. Over five years, the stock has surged 146.85%, dwarfing the Sensex’s 31.07% gain. However, the ten-year return of 143.74% trails the Sensex’s 164.07%, reflecting a period of relative underperformance in the distant past. These figures highlight the company’s capacity for sustained growth, tempered by cyclical and sector-specific challenges. The interplay of these long-term trends with recent short-term volatility adds complexity to the investment thesis.

Conclusion: A Balanced Data-Driven View

The data on Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading close to its industry valuation, with strong long-term returns but mixed short-term momentum. The moving average configuration suggests a recovery phase within a broader uptrend, yet recent price softness and a three-day losing streak indicate caution. The sector’s mixed results further complicate the outlook, while the recent rating reassessment from Buy to Hold by MarketsMOJO reflects these nuanced dynamics. Investors are left to weigh these factors carefully — what is the current rating?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today